Novelion Therapeutics (NVLN) Reports Q1 EPS of $0.47, Beats on Revenues; Reiterates FY17 Revenue Guidance

Novelion Therapeutics (NASDAQ: NVLN) reported Q1 EPS of $0.47. Revenue for the quarter came in at $30 million versus the consensus estimate of $13.57 million.

GUIDANCE:

Novelion Therapeutics sees Q2 2017 revenue of $155-165 million.

2017 Financial Guidance

The Company reiterated the following net revenues financial guidance for full year 2017:

• Total net revenues between $155 million and $165 million;
• MYALEPT net revenues between $75 million and $80 million; and
• JUXTAPID net revenues between $80 million and $85 million.

The Company intends to provide full year 2017 operating expense guidance upon conclusion of its ongoing R&D program review and prioritization this summer. As part of this review, Novelion continues to identify and implement cost-reduction initiatives.

For earnings history and earnings-related data on Novelion Therapeutics (NVLN) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Rekor Systems, Inc. (REKR) Tops Q2 EPS by 3c
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance